系列N-of-1试验评估两种依那普利制剂治疗亚的斯亚贝巴高血压患者的治疗可互换性:随机对照试验研究方案
该研究方案采用医院为基础的随机、部分盲法、三周期交叉N-of-1试验,比较埃塞俄比亚本地生产与欧洲进口的依那普利(5-20 mg每日一次)治疗高血压的疗效。主要结局为家庭血压测量的收缩压平均差异,旨在为本地仿制药的治疗等效性提供严格证据,并评估在资源有限国家开展聚合N-of-1研究的可行性。
要点
- 采用三周期交叉N-of-1设计比较本地与进口依那普利治疗高血压。
- 每周期为连续14天治疗对,含7天本地与7天进口依那普利5-20 mg每日一次。
- 主要结局为家庭血压测量的收缩压平均差异。
核心结论
- 该试验将为本地生产依那普利治疗高血压的治疗等效性提供严格证据;若无差异(假设结果),患者可放心使用本地药物;该试验还将确定聚合N-of-1研究在无法进行生物等效性检测的资源有限国家评估未测试仿制药的可行性。
研究设计与样本
- 医院为基础的随机、部分盲法、三周期交叉N-of-1试验,比较本地生产依那普利与欧洲进口依那普利。
- 患者不设盲,因当地无设施生产少量安慰剂或胶囊化药物;研究药物由独立药房使用不透明包装准备,以确保研究者和数据分析者盲法。
- 每个N-of-1试验包含三个连续的14天治疗对,每个治疗对包括7天本地依那普利5-20 mg和7天进口依那普利5-20 mg,每日早晨一次口服。
关键数值与推荐
- 主要结局为家庭血压测量的收缩压平均差异。
- 本地依那普利剂量为5-20 mg每日一次,进口依那普利剂量为5-20 mg每日一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 患者不设盲,因当地无设施生产少量安慰剂或胶囊化药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertension is one of the leading causes of morbidity and mortality in Ethiopia. Treatment usually involves lifelong medication use. Enalapril is a common drug for the treatment of hypertension in Ethiopia. However, the drug is expensive and, therefore, there is limited capacity for people to afford the treatment. Locally produced Enalapril is a cost-effective solution to treat the disease. However, as local medicines regulation does not include bioequivalence tests on locally produced drugs, physicians and patients need assurance about the effectiveness and safety of local generics. Evidence on therapeutic equivalence is needed on these untested local drugs. METHODS: This is a hospital-based, randomized, partially blinded, three-cycle crossover trial in single patients, comparing a locally produced version of enalapril with enalapril imported from Europe. Patients involved in this trial are not blinded, as there is no local facility to produce relatively small numbers of placebos or encapsulated drugs. To ensure blinding of study investigators and data analysts, study medications are prepared by an independent pharmacy unit using opaque medication packaging. The importance of maintaining blinding is also part of patient pre-trial education. Each N-of-1 trial will consist of three successive 14-day treatment pairs, each pair comprising 7 days of 5-20 mg local and 7 days of 5-20 mg imported enalapril taken once daily in the morning. The primary outcome will be the average difference in systolic blood pressure as measured by home blood pressure measurements. DISCUSSION: The number of locally produced products, such as enalapril, being approved without proof of bioequivalence is dramatically increasing. By bridging the information gap on bioequivalence, the trial will give rigorous evidence on therapeutic equivalence of locally produced enalapril in the treatment of hypertension. If there is no difference, the hypothesized result, then patients can take the local medicine with confidence. This trial will also will determine whether aggregated N-of-1 studies are feasible to evaluate untested generic drugs in resource-limited countries where bioequivalence testing centers are unavailable. TRIAL REGISTRATION NUMBER: Australian and New Zealand Clinical Trial Registry, ID: ACTRN12616001088437p . Registered on 12 August 2016.
引用
- Alemayehu C, Mitchell G, Aseffa A, et al. A series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial. Trials. 2017. PMID: 29017595. doi:10.1186/s13063-017-2212-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。